Baseline characteristics and outcomes of the FOURIER and ODYSSEY Outcomes trials
| Parameter . | FOURIER . | ODYSSEY Outcomes . | ||
|---|---|---|---|---|
| Antibody . | Evolocumab . | Alirocumab . | ||
| Study group . | Placebo (n = 13 780) . | Evolocumab (n = 13 784) . | Placebo (n = 9462) . | Alirocumab (n = 9462) . |
| eGFR exclusion criterion | <20 mL/min/1.73 m2 | <30 mL/min/1.73 m2 | ||
| Median length of follow-up (years) | 2.2 | 2.8 | ||
| MI (%) | 81.3 | 80.9 | 82.8 | 83.4 |
| Median time from previous MI (months) | 39.6 | 40.8 | 2.8 | 2.8 |
| High-intensity statin therapy (%) | 69.1 | 69.5 | 89.1 | 88.6 |
| Moderate-intensity statin therapy (%) | 30.7 | 30.2 | 8.2 | 8.8 |
| Ezetemibe therapy (%) | 5.2 | 5.3 | 3.0 | 2.8 |
| Baseline LDL-C (mg/dL) | 92 | 92 | 92 | 92 |
| Baseline LDL-C (mmol/L) | 2.39 | 2.39 | 2.39 | 2.39 |
| Change of LDL-C (%) | −59 | −54.7 | ||
| Primary endpoint (RRR, %) | 15 | 15 | ||
| Key secondary endpoint (RRR, %) | 20 | 14 | ||
| Parameter . | FOURIER . | ODYSSEY Outcomes . | ||
|---|---|---|---|---|
| Antibody . | Evolocumab . | Alirocumab . | ||
| Study group . | Placebo (n = 13 780) . | Evolocumab (n = 13 784) . | Placebo (n = 9462) . | Alirocumab (n = 9462) . |
| eGFR exclusion criterion | <20 mL/min/1.73 m2 | <30 mL/min/1.73 m2 | ||
| Median length of follow-up (years) | 2.2 | 2.8 | ||
| MI (%) | 81.3 | 80.9 | 82.8 | 83.4 |
| Median time from previous MI (months) | 39.6 | 40.8 | 2.8 | 2.8 |
| High-intensity statin therapy (%) | 69.1 | 69.5 | 89.1 | 88.6 |
| Moderate-intensity statin therapy (%) | 30.7 | 30.2 | 8.2 | 8.8 |
| Ezetemibe therapy (%) | 5.2 | 5.3 | 3.0 | 2.8 |
| Baseline LDL-C (mg/dL) | 92 | 92 | 92 | 92 |
| Baseline LDL-C (mmol/L) | 2.39 | 2.39 | 2.39 | 2.39 |
| Change of LDL-C (%) | −59 | −54.7 | ||
| Primary endpoint (RRR, %) | 15 | 15 | ||
| Key secondary endpoint (RRR, %) | 20 | 14 | ||
RRR, relative risk reduction.
Baseline characteristics and outcomes of the FOURIER and ODYSSEY Outcomes trials
| Parameter . | FOURIER . | ODYSSEY Outcomes . | ||
|---|---|---|---|---|
| Antibody . | Evolocumab . | Alirocumab . | ||
| Study group . | Placebo (n = 13 780) . | Evolocumab (n = 13 784) . | Placebo (n = 9462) . | Alirocumab (n = 9462) . |
| eGFR exclusion criterion | <20 mL/min/1.73 m2 | <30 mL/min/1.73 m2 | ||
| Median length of follow-up (years) | 2.2 | 2.8 | ||
| MI (%) | 81.3 | 80.9 | 82.8 | 83.4 |
| Median time from previous MI (months) | 39.6 | 40.8 | 2.8 | 2.8 |
| High-intensity statin therapy (%) | 69.1 | 69.5 | 89.1 | 88.6 |
| Moderate-intensity statin therapy (%) | 30.7 | 30.2 | 8.2 | 8.8 |
| Ezetemibe therapy (%) | 5.2 | 5.3 | 3.0 | 2.8 |
| Baseline LDL-C (mg/dL) | 92 | 92 | 92 | 92 |
| Baseline LDL-C (mmol/L) | 2.39 | 2.39 | 2.39 | 2.39 |
| Change of LDL-C (%) | −59 | −54.7 | ||
| Primary endpoint (RRR, %) | 15 | 15 | ||
| Key secondary endpoint (RRR, %) | 20 | 14 | ||
| Parameter . | FOURIER . | ODYSSEY Outcomes . | ||
|---|---|---|---|---|
| Antibody . | Evolocumab . | Alirocumab . | ||
| Study group . | Placebo (n = 13 780) . | Evolocumab (n = 13 784) . | Placebo (n = 9462) . | Alirocumab (n = 9462) . |
| eGFR exclusion criterion | <20 mL/min/1.73 m2 | <30 mL/min/1.73 m2 | ||
| Median length of follow-up (years) | 2.2 | 2.8 | ||
| MI (%) | 81.3 | 80.9 | 82.8 | 83.4 |
| Median time from previous MI (months) | 39.6 | 40.8 | 2.8 | 2.8 |
| High-intensity statin therapy (%) | 69.1 | 69.5 | 89.1 | 88.6 |
| Moderate-intensity statin therapy (%) | 30.7 | 30.2 | 8.2 | 8.8 |
| Ezetemibe therapy (%) | 5.2 | 5.3 | 3.0 | 2.8 |
| Baseline LDL-C (mg/dL) | 92 | 92 | 92 | 92 |
| Baseline LDL-C (mmol/L) | 2.39 | 2.39 | 2.39 | 2.39 |
| Change of LDL-C (%) | −59 | −54.7 | ||
| Primary endpoint (RRR, %) | 15 | 15 | ||
| Key secondary endpoint (RRR, %) | 20 | 14 | ||
RRR, relative risk reduction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
